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ABSTRACT 
Background 
Achalasia is an uncommon condition characterised by failed lower oesophageal sphincter relaxation. 
Data regarding its incidence, prevalence, disease associations and long term outcomes are very 
limited.  
Methods 
Hospital Episode Statistics (HES) include demographic and diagnostic data for all English hospital 
attendances. The Health Improvement Network (THIN) includes the primary care records of 4.5 
million UK subjects, representative of national demographics. Both were searched for incident cases 
between 2006 and 2016 and THIN for prevalent cases. Achalasia subjects in THIN were compared 
with age, sex, deprivation and smoking status matched controls, for important co-morbidities and 
mortality. 
Results 
There were 10,509 and 711 new achalasia diagnoses identified in HES and THIN respectively. The 
mean incidence per 100,000 people in HES was 1.99(95% CI 1.87-2.11) and 1.53(1.42-1.64) per 
100,000 person years in THIN. The prevalence in THIN was 27.1(25.4-28.9) per 100,000 population. 
Incidence Rate Ratios (IRR) were significantly higher in achalasia subjects (n=2,369) compared to 
controls (n=3,865) for: oesophageal cancer (IRR 5.22(95%CI: 1.88-14.45),p<0.001), aspiration 
pneumonia (13.38(1.66-107.79),p=0.015), lower respiratory tract infection (1.33(1.05-1.70),p=0.02) 
and mortality (1.33(1.17-1.51),p<0.001). The median time from achalasia diagnosis to oesophageal 
cancer diagnosis was 15.5(IQR 20.4) years. 
Conclusion 
The incidence of achalasia is 1.99 per 100,000 population in secondary care data and 1.53 per 
100,000 person years in primary care data. Subjects with achalasia have an increased incidence of 
oesophageal cancer, aspiration pneumonia, lower respiratory tract infections and higher mortality. 
Clinicians treating patients with achalasia should be made aware of these associated morbidities and 
its increased mortality. 
  
 
 
  
3 
 
  What is already known on this subject? 
 Achalasia is uncommon, but data on its incidence and 
prevalence are unclear.  
 An association to oesophageal cancer has been reported. 
What are the new findings? 
 Incidence of achalasia is 1.99 per 100,000 population and 
1.53 per 100,000 person years based on secondary care 
and primary care data respectively. 
 Achalasia prevalence is 27.1 per 100,000 people. 
 Oesophageal cancer is over 5 times more likely in 
achalasia patients, presenting on average 15 years after 
diagnosis. 
 Achalasia is associated with increased mortality and an 
increased risk of respiratory tract infections. 
How might these findings impact on clinical practice in the 
foreseeable future? 
 Incidence and prevalence data should inform service 
planning for therapy for this condition. 
 The time to diagnosis of oesophageal cancer should be 
taken into account when considering screening for this 
patient group. 
 Clinicians should be more vigilant for respiratory tract 
infections in this patient group 
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INTRODUCTION 
Achalasia is characterised by a lack of relaxation of the lower oesophageal sphincter. Symptom onset 
is typically insidious, with several years of dysphagia, regurgitation and progressive weight loss until 
a diagnosis is made. It has a substantial impact on quality of life through making meal times 
miserable.  
 
Only limited data exist to describe the epidemiology of achalasia. The reported incidence of 
achalasia varies between 0.03 per 100,000 in a Zimbabwean population(1), 1.07 per 100,000 in 
Chicago in the United States of America(2), and 1.63 per 100,000 in Canada(3). However these 
studies included small cohorts of only 25, 379 and 463 subjects with achalasia respectively. The 
largest UK  study, in 1987, reported an incidence of 0.9 per 100,000 people but was derived only 
from hospital data(4). Estimates of achalasia prevalence have similar limitations. 
 
Left untreated the clinical progress of achalasia subjects includes gradual dilatation of the 
oesophagus and eventual mega-oesophagus. However, there is little data available to describe the 
long term impact of achalasia following diagnosis and therapy.   Life expectancy in patients with 
achalasia has been previously reported to be similar to background population but these estimates 
were derived from cases series rather than population based data(5). Several studies have suggested 
an association between achalasia and oesophageal cancer(6, 7), leading to debate regarding the 
potential value of endoscopic screening for this patient group.  
 
We have therefore examined the incidence, prevalence, associated morbidity and mortality of 
subjects with achalasia in two national patient databases.  
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MATERIALS AND METHODS  
Data Sources 
Hospital Episode Statistics 
Hospital Episode Statistics (HES) are recorded to deliver administrative functions such as payment to 
secondary care providers in England. HES has also been made available for secondary research 
purposes. Unique identification codes link each admission episode to individual patients enabling 
longitudinal analysis. Available data includes diagnostic codes (International classification of diseases 
10 (ICD-10)), demographic and administrative data. HES includes procedures performed as an 
outpatient in secondary care such as endoscopy.   
 
The Health Improvement Network 
The Health Improvement Network (THIN) represents a group of General Practices (primary care) 
covering 6% of the UK population, which is representative of the UK population structure(8). 
Diagnosis and clinical presentations are recorded as Read codes, a hierarchical coding system(9). 
Additional information includes demographic, laboratory and prescription data. Individual practices 
were eligible for inclusion in the study from the later of the following two dates to ensure that the 
practice was making full use of the Electronic Medical Record (EMR): one year after the date their 
EMR was installed; and after the practice’s acceptable mortality recording date. To ensure there was 
sufficient time to record baseline co-morbidities data, individual subjects were eligible for inclusion 
from the date their practice became eligible for inclusion in the study or one year after registration 
with their practice if this date was later.  
 
Validation 
HES data were validated by interrogation of local endoscopy reporting software, an oesophageal 
manometry database and surgical operation logs during the study period at Sandwell and West 
Birmingham Hospitals NHS Trust. All subjects with achalasia listed as a reported finding, prior 
diagnosis or indication were collated and electronic records were then hand searched to ensure 
suitability for inclusion in the study. This figure was then compared to the equivalent data generated 
from HES. There is no current mechanism to validate THIN data, however the data integrity is 
supported by the stringent minimum data quality standards described above. 
 
Incidence and Prevalence Data 
HES were searched for any subject with a diagnostic code in the primary position for achalasia 
(appendix A) from 1st of January 2006 to 31st Dec 2015. The code may be associated with any 
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hospital attendance including outpatient consultation, endoscopy or other diagnostic test, or for 
treatment and complications of achalasia.  Subjects were considered to have an existing diagnosis if 
a diagnostic code for achalasia was present in HES at any time prior to this period. Sex, Index of 
Multiple Deprivations and Ethnicity were extracted for this group. Incidence was calculated using 
annual mid-year England population figures provided by the Office for National Statistics and 
reported per 100,000 population with 95% Confidence Intervals. HES data only includes subjects in 
England, rather than the whole UK, and the incidence was calculated on the  basis of the source 
population (approximately 50 million persons). 
 
THIN was searched using the READ code for achalasia for both new and previously diagnosed cases 
of achalasia (appendix B) as communicated from secondary care. Incidence is reported annually per 
100,000 person years with 95% confidence intervals and prevalence as on 1st of January each year 
per 100,000 populations with 95% confidence intervals.  
 
Retrospective Cohort Study of morbidity and mortality outcomes in the THIN database 
For outcome analysis only THIN database was utilised because it is possible to generate controls 
from the source population to compare outcomes. The index date of the achalasia subjects in THIN 
were defined as the date they were eligible to take part in the study if they already had a diagnosis 
of achalasia, or the date they were diagnosed with achalasia if they were incident cases. Achalasia 
subjects in THIN were matched for age at index date (within 2 years), sex, deprivation (Townsend 
deprivation score) and smoking status to two control subjects without a diagnosis of achalasia. The 
controls were selected from the same general practice as the matched case. Group demographics 
and incidence rates for pre-specified outcomes of interest were calculated for achalasia and control 
groups during the study period from 1st January 1996 to the 1st September 2015. New outcome 
codes were sought in matched groups from the index date until the first of the following outcomes 
occurred (exit date); subject died, subject left practice, last data collection from practice, study end 
date or subject diagnosed with the outcome of interest. Subjects were excluded if there was a 
diagnosis of the outcome of interest prior to achalasia diagnosis.  Subjects were also excluded from 
the study if they had a diagnosis of oesophageal cancer within one year of achalasia diagnosis, or if 
they had a diagnosis of Chagas’ disease. 
  
Prospectively determined new outcomes included: any cardiovascular disease (including ischaemic 
heart disease, stroke or TIA, and heart failure), oesophageal cancer, any cancer (excluding 
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oesophageal), peripheral vascular disease, aspiration pneumonia, lower respiratory tract infection 
(LRTI), dementia and all-cause mortality (Appendix B). 
  
Statistical Analysis 
The matched groups baseline characteristics in THIN are described in proportions for categorical 
variables (sex, Townsend deprivation score, smoking status, hypertension, diabetes mellitus, and use 
of lipid lowering medications) and with mean (standard deviation) for normally distributed 
continuous variables (age and BMI) and Mann-Whitney U test  for skewed continuous variables 
(person years).  
 
An estimated incidence rate ratio (IRR) was calculated for each outcome within the achalasia and 
control groups. Then adjusted IRRs were calculated using the Poisson regression for individual 
patient covariates (age, sex, Townsend deprivation score, smoking status, hypertension, diabetes 
mellitus and the use of lipid lowering medications) as appropriate. “Any cardiovascular disease”, 
stroke or TIA, heart failure and peripheral vascular disease were further adjusted for diabetes, lipid 
lowering drug use and hypertension. The median and interquartlie range (IQR) of time from 
achalasia diagnosis to oesophageal cancer, LRTI and death is also reported. In control subjects, start 
time was considered to be the time of study entry. Cumulative incidence plots were constructed for 
time to oesophageal cancer, LRTI and all cause mortality. BMI was treated as a categorical variable 
to address missing values. Mortality was adjusted for Charlson Score in addition to the factors listed 
above. The Charlson score is based on a list of co-morbidities, each with an assigned score. The sum 
of a patient’s individual co-morbidity scores is the final score(10). Incidence rate ratios were 
calculated with 95% confidence and a statistical significance threshold of p<0.05. 
 
All analysis was conducted using Stata v14.0 software(11). The THIN data collection scheme received 
multi-centre research ethics committee (MREC) approval in 2003 with scientific committee approval 
of this particular study in March 2017 (SRC17THIN133) from ‘IMSHealth’ (data provider). 
Pseudonymised HES data has been shared by NHS Digital under a data sharing agreement for the 
purpose of service evaluation including estimation of disease burden. Ethical approval is not 
required for HES studies. 
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RESULTS 
Validation 
At Sandwell and West Birmingham Hospital NHS Trust there were 56 subjects with a new diagnosis 
of achalasia within the study period. This correlates strongly (96%) with the 54 coded for within the 
HES database for Sandwell and West Birmingham Hospitals NHS Trust during the study period. 
 
Subject demographics 
The HES subjects included 10,509 incident cases of achalasia in England over a 10 year period. The 
median age was 59 (IQR 43-75) years and the cohort was split evenly with respect to sex (49.7% 
male, 50.3% female). The THIN subjects included 711 incident achalasia diagnoses in the UK. The 
median age was 62 (IQR 45-75) years and the cohort was split evenly with respect to sex (47.1% 
male, 52.9% female). Full cohort demographics are shown in table 1.  
 
Incidence and prevalence of achalasia 
The overall incidence per 100,000 population over the study period in HES was 1.99 (95% CI 1.87-
2.11) and 1.53 (1.42-1.64) per 100,000 person years in THIN. The mean prevalence measured in THIN 
was 27.1 (25.4-28.9) per 100,000 population. The incidence seen in HES increased over the study 
period from 1.73(1.62-1.85) in 2006 to 2.24(2.11-2.36) per 100,000 population in 2015. A similar 
increase was not observed in achalasia subjects in THIN. The annual incidence and prevalence from 
each database is presented in table 2. 
 
Demographics and co-morbidity in the matched achalasia and control groups 
There were 2,369 achalasia cases matched to 3,865 controls within THIN. There was a mean of 6.1 
(SD 5.4) and 6.4 (5.4) person years follow-up for achalasia subjects and controls respectively. 
Achalasia subjects were slightly older as they were matched to within 2 years (56.7 vs. 55.5 years, 
p=0.03), however there was no difference in sex, BMI or deprivation index quintile. The incidence of 
hypertension(506(21%) vs. 928(24%), p=0.016), diabetes(126(5.3%) vs. 278(7.2%), p=0.004) and lipid 
lowering medication use(342(14.4%) vs. 635(16.4%), p=0.04) was lower in the achalasia cohort 
compared to the matched controls(table 3).   
 
Morbidity outcomes in the matched achalasia and control groups 
Following adjustment for potential confounding factors, oesophageal cancer was more common in 
the achalasia group compared to the control group; adjusted IRR 5.22 (95% CI 1.88-14.45), p=0.001. 
Also more common in the achalasia group were aspiration pneumonia 13.4(1.7-107.8), p=0.015 and 
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lower respiratory tract infection (LRTI) 1.3(1.1-1.7), p=0.02 (table 4). The incidence of ischeamic 
heart disease, peripheral vascular disease, heart failure, dementia and cancer (excluding 
oesophageal cancer) did not differ between the groups. The median time from achalasia diagnosis to 
oesophageal cancer and LRTI was 15.5 (IQR 5.8-26.2) and 7.5 (1.5–13.6) years respectively. 
Cumulative incidence plots of the time from achalasia diagnosis to oesophageal cancer and LRTI are 
displayed in figures 1 and 2 respectively. 
 
Mortality in achalasia subjects 
There were 441 deaths in 14,321 person years in the achalasia group compared to 553 deaths in 
24,594 person years in the control group. The incidence rate ratio was 1.37 (1.21-1.55). Mortality 
remained significantly higher in the achalasia group despite adjusting for Charlson score, BMI, age, 
sex, smoking status, diabetes, lipid lowering drug use and hypertension; adjusted IRR 1.33(95% CI 
1.2-1.5, p<0.001)(table 5). The median time to death was 6.8 (IQR 0.6-12.9) years. The cumulative 
incidence plot of time from achalasia diagnosis to death is displayed in figure 3. 
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DISCUSSION 
 
The incidence of achalasia in England was between 1.42 and 2.11 per 100,000 between 2006 and 
2016 and its prevalence 27.1 per 100,000. Both the incidence and prevalence are higher than 
previously thought in the UK population. A previously unrecognised increased mortality in achalasia 
subjects has been demonstrated, as has an association between achalasia and aspiration pneumonia 
and lower respiratory tract infections. Furthermore this study confirms a significant association 
between oesophageal cancer and achalasia with a fivefold higher incidence in achalasia. 
 
There are limited recent data on the incidence and prevalence of achalasia. Although significantly 
higher than the incidence reported in the largest English study (0.9 per 100,000)(4), the results 
reported here are in keeping with the incidence reported in a more recent Canadian study, which 
reported an incidence of 1.63(95% CI 1.2-2.1) per 100,000(3). However the prevalence reported in 
the current study is significantly higher than that reported in Canada (10.8(9.7-11.9)). A potential 
reason for this discrepancy is due to case finding, as any achalasia subject was included in the 
present study, whereas the Canadian study only included subjects attending for treatment by 
pneumatic dilatation or surgical myotomy. Therefore any subject in the Canadian study that did not 
present for treatment would not be included. Although the authors have validated their data 
showing excellent sensitivity and specificity, the validation population were those attending for 
treatment. This important source of bias was not addressed in the prevalence analysis. 
  
High resolution manometry diagnoses achalasia more accurately and provides information on 
subtypes that is relevant to response to therapy(12). The widespread use of high resolution 
manometry might be expected to marginally increase the incidence of achalasia and such a rise in 
incidence over time was seen in the HES database but not the THIN database.  
 
An association with oesophageal cancer has been previously reported in achalasia. The mechanism is 
not understood, but, it has been postulated that poor oesophageal emptying leads to stasis and 
inflammation and subsequently dysplasia and eventually to neoplasia(13). Estimates of the 
magnitude of the increased risk vary. In a Swedish cohort study a 16-fold increase (SIR 16.6(8.8-
28.3))(7) has been reported. However a more recent Swedish study described a 10-fold increase (SIR 
10.5(7.0-15.9)) in risk of oesophageal cancer(6). The higher background UK oesophageal cancer 
incidence compared to Sweden is likely to have reduced the relative increase in risk in achalasia 
subjects in the present study. The median time from achalasia diagnosis to oesophageal cancer was 
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15.5 (IQR 5.8-26.2)years. This estimate is imprecise due to the small number of observed events, as 
oesophageal cancer remains a rare event even in this population. It is therefore not possible to 
discern a discrete period of increased risk following achalasia diagnosis, however cancers within 5 
years of diagnosis appear uncommon. Unfortunately, a limitation of the present study is the inability 
to distinguish between oesophageal squamous cell carcinoma and oesophageal adenocarcinoma, as 
neither database is linked to a cancer registry.  
 
Several case reports describe recurrent respiratory tract infections in the presence of recently or 
undiagnosed achalasia(14-16). There are no population based studies that have previously 
demonstrated an association between achalasia and aspiration pneumonia or lower respiratory tract 
infection (LRTI). The peak incidence of LRTI was 7.5 years following diagnosis, however, the 
cumulative incidence plot (figure 2) suggests this event occurs regularly in the years following 
diagnosis. 75% of these episodes occurred at least 18 months after diagnosis but a small proportion 
of LRTIs may be related to initial achalasia treatment (surgery or pneumatic dilatation). However it  
seems likely that generally this association represents the same process as may contribute to 
oesophageal cancer, i.e. incomplete emptying of the oesophagus with consequent risk of aspiration 
of oesophageal contents.  
 
More subjects died in the achalasia group compared to the matched controls when adjusted for a 
number of risk factors. The median time to death was 6.8 (IQR 0.6-12.9) years, potentially coinciding 
with both any peri-procedural mortality from treatment (17) and excess LRTI in this group. However, 
these factors alone may be insufficient to explain the increased mortality. The increased incidence of 
oesophageal cancer is also likely to contribute, but this cause of increased mortality is later in the 
natural history and uncommon. Unfortunately the cause of death as stated on the death certificates 
was not available in this study. Although mortality in achalasia has been investigated previously in a 
tertiary centre case series, in that study, no increase in mortality was reported(5).  
 
This analysis is dependent upon accurate coding of achalasia and associated diagnoses. The data 
provided by HES has been validated, demonstrating high levels of agreement in an individual 
provider. Data completeness can also supported by comparison of the median age to other studies 
including Samo (median age 56)(2) and Enestvedt (mean age 62)(18) compared to 59 in HES and 62 
in THIN. Unfortunately oesophageal manometry data were not available within HES or THIN to 
support the coded diagnosis of achalasia. THIN data is centrally quality controlled, therefore 
providing reassurance that coding is accurate. However as the diagnosis is established in secondary 
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care, the primary care Read codes are dependent on accurate communication. Therefore 
ascertainment bias may lead to under-estimation of the incidence and prevalence of achalasia in 
THIN data. This potentially explains the variation in incidence between the two datasets, although 
this is small with the peak discrepancy between 95% CI 0.38 per 100,000. However, the similarity 
seen between data from THIN and HES is reassuring. A diagnosis of achalasia will be made in a 
hospital setting and recorded on HES, and then coded in THIN once the diagnosis is communicated 
to primary care. The similarity in incidence figures between the datasets supports the accuracy of 
coding and subsequent case ascertainment.    
 
Several risk factors for oesophageal cancer were not available for this analysis. The prevalence of 
acid reflux, alcohol and dietary information were not available, therefore they could not be included 
in the matching or corrected for in the analysis. However groups were matched by age, sex, smoking 
status and deprivation. In addition mortality was also corrected for Charlson score.  The use of two 
national databases to address the same question increases confidence in the accuracy of the 
incidence of achalasia reported here. THIN and HES are independent of each other, utilising different 
coding systems and different sources of clinical data. Therefore it is reassuring that the variation in 
reported incidence is small. This is also the largest epidemiological description of achalasia ever 
reported, including over 11,000 cases with no study since Mayberry et al in 1987 having reported 
more than 1000 cases (4).  
 
This is the first study to report from population based data on increased mortality and key 
morbidities associated with achalasia. Our findings are crucial to the prevention of LRTI in achalasia 
through, for example, encouraging smoking cessation, and to the consideration of screening and risk 
factor modification (smoking and alcohol intake) for oesophageal cancer in subjects with achalasia. 
Clinical guidelines should consider highlighting identified complications of achalasia and urge 
vigilance among the clinicians to detect and manage them early. Future studies should aim to 
replicate our findings in other nations.  
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Table 1: The demographics of the Hospital Episode Statistics and The Health Improvement 
Network achalasia subjects 
 
    HES THIN 
Sex Male 5226 (49.7) 335 (47.1) 
Female 5283 (50.3) 376 (52.9) 
Age  
(median, IQR) 
 59 (43-75) 62 (45-75) 
Deprivation 
Quintile*  
 
 
 
 
 
Most deprived quintile 1848 (17.6) 80 (11.3) 
2nd  most deprived quintile 2094 (19.9) 124 (17.4) 
Middle quintile 2176 (20.7) 161 (22.6) 
2nd least deprived quintile 2199 (20.9) 148 (20.8) 
Least deprived quintile 2173 (20.7) 176 (24.8) 
Unknown 19 (0.0) 22 (3.1) 
Ethnic 
Group** 
White 9117 (86.8) 301 (42.3) 
Asian or Asian British 79 (0.8) 17 (2.4) 
Black or Black British 480 (4.6) 9 (1.3) 
Mixed 282 (2.7) - 
Any other ethnic group 176 (1.7) - 
Unknown 375 (3.6%) 384 (54.0) 
 
*HES uses Index of multiple deprivations (2010), quintile 1 is the most deprived. THIN uses 
Townsend  index, quintile 5 is the most deprived. Therefore this is displayed from most to least 
deprived quintiles. 
 
** THIN was found to include multiple ethnicities per subject depending on the scale applied. 
Therefore when there was ambiguity subjects were listed as unknown.  
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Table 2 The incidence and prevalence of achalasia reported in Hospital Episode Statistics and The 
Health Improvement Network by year 
 
Year Incidence 
rate HES 
95% CI Incidence 
rate THIN 
95% CI Prevalence 
rate THIN 
95% CI 
2006 
 
1.73 1.62-1.85 1.41 1.01-1.74 21.14 19.79-22.56 
2007 
 
1. 80 1.69-1.92 1.66 1.08-1.81 21.72 20.37-23.14 
2008 
 
1.80 1.68-1.91 1.55 1.30-2.08 22.49 21.12-23.91 
2009 
 
1.85 1.74-1.97 1.70 1.21-1.96 23.16 21.79-24.6 
2010 
 
2.02 1.90-2.14 1.66 1.34-2.12 23.66 22.27-25.12 
2011 
 
1.78 1.67-1.90 1.42 1.31-2.09 24.62 23.19-26.12 
2012 
 
2.03 1.91-2.16 1.55 1.20-1.96 25.23 23.77-26.76 
2013 
 
2.18 2.06-2.31 1.62 1.26-2.05 26.06 24.56-27.62 
2014 
 
2.42 2.29-2.56 1.48 1.11-1.91 26.34 24.78-27.97 
2015 
 
2.24 2.11-2.36 1.34 0.96-1.80 27.10 25.44-28.85 
  
HES – Hospital Episode Statistics 
THIN – The Health Improvement Network 
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Table 3 The Health Improvement Network achalasia and matched control groups characteristics 
  Achalasia 
Cases  
Control 
Cases  
P value 
Number of subjects 
 
2,369 3,865 - 
Person years of follow-up 
(SD) 
6.1 (5.4) 6.4 (5.4) 0.02 
Age (SD) 56.6 (19.8) 55.5 (19.3) 0.03 
Male Sex 1166 (49.2%) 1902 (49.2%) 0.995 
Body mass index (SD) 25.62 (5.3) 25.37  (4.1) 0.07 
Current smoking 379 (16%) 573 (14.8%) 0.211 
Hypertension 506 (21%) 
 
928 (24%) 0.016 
Lipid regulating 
medications 
342 (14.4%) 635 (16.4%) 0.04 
Diabetes mellitus 
 
126 (5.3%) 278 (7.2%) 0.004 
Charlson Co-morbidity 
score: 0 
1468 (62.0%) 2550 (66.0%) 0.001 
1 496 (20.9%) 797 (20.6%) 
2 220 (9.3%) 285 (7.4%) 
3 110 (4.6%) 129 (3.3%) 
>3 75 (3.2%) 104 (2.7%) 
Townsend index*: 1     1026 (27%) 592 (25%) 0.377 
2 890 (23%) 525 (22%) 
3 776 (20%) 482 (21%) 
4 612 (16%) 390 (17%) 
5 400 (10%) 267 (11%) 
Not available 108 (3%) 81 (3%) 
 
*1 is the least deprived group for Townsend deprivation index 
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Table 4 Comparison of disease outcomes between achalasia cases and matched controls in The Health Improvement Network 
   
  All 
Cardiovascul
ar Disease 
Ischaemic 
Heart 
Disease 
Stroke/TIA Heart Failure Peripheral 
Vascular 
Disease 
Oesophageal 
Cancer 
Any Cancer Aspiration 
Pneumonia 
LRTI Dementia 
  Case  Contr
ol 
Case  Contr
ol 
Case  Contr
ol 
Case  Contr
ol 
Case  Contr
ol 
Case  Contr
ol 
Case  Contr
ol 
Case  Contr
ol 
Case  Contr
ol 
Case  Contr
ol 
No. 
Subjects 
2,03
3 
3,36
9 
2,14
7 
3,52
0 
2,26
2 
3,70
6 
2,28
9 
3,77
6 
2,30
3 
3,80
1 
2,36
6 
3,86
3 
2,22
6 
3,69
9 
2,35
9 
3,86
4 
2,26
3 
3,74
4 
2,33
8 
3,82
4 
No. of 
Outcomes 
278 451 128 242 113 182 97 120 63 73 16 6 150 224 9 1 135 170 86 127 
Person-
years 
15,37
9 
26,02
7 
15,98
5 
26,81
8 
16,21
8 
27,50
3 
16,30
6 
27,84
1 
16,37
9 
27,92
5 
16632 28229 16,07
1 
27,42
0 
16,61
7 
28,23
5 
16,20
7 
27,63
0 
16,46
8 
27,98
1 
Incidence 
Rate (per 
1000 
person-
years) 
18.1 17.3 8.0 9.0 7.0 6.6 5.9 4.3 3.8 2.6 1.0 0. 2 9.3 8.2 0. 5 0.04 8.3 6.2 5.2 4.5 
Incidence 
Rate Ratio 
(95% CI) 
1.01 
(0.83-1.21) 
0.97 
(0.74 - 1.26) 
1.02 
(0.79-1.31) 
1.27 
(0.94-1.72) 
1.21 
(0.82-1.78) 
5.09 
(1.85-14.01) 
1.12 
(0.89-1.40) 
13.62 
(1.70-108.87) 
1.34 
(1.05-1.70) 
1.11 
(0.82-1.49) 
p-value 0.958 0.802 0.892 0.118 0.331 0.002 0.3333 0.014 0.018 0.507 
Adjusted 
Incidence 
Rate Ratio 
(95% CI) 
1.04 
(0.86-1.26) 
1.00 
(0.76-1.31) 
0.99 (0.77-
1.28) 
1.32 
(0.97-1.80) 
1.31 
(0.88-1.94) 
5.22 
(1.88-14.45) 
1.10 
(0.88-1.38) 
13.38 
(1.66-107.79) 
1.33 
(1.05-1.70) 
1.10 
(0.82-1.50) 
p-value 0.714 0.993 0.953 0.077 0.186 0.001 0.413 0.015 0.02 0.521 
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Table 5 Mortality in achalasia subjects and controls in The Health Improvement Network 
  Achalasia Control 
Number of Subjects 2,369 3,865 
Numbers of deaths 441 553 
Person-years 14321 24594 
Incidence Rate (per 100 person-years) 3.08 2.25 
Incidence Rate Ratio (95% Confidence 
intervals) 
1.37 (1.21-1.55) 
p-value <0.001 
Incidence Rate Ratio (95% Confidence 
intervals) adjusted* 
1.33 (1.17-1.51) 
p-value <0.001 
 
* Adjusted for Charlson Score, Body mass index, age, sex, smoker, diabetes, lipid lowering 
drugs and hypertension 
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Figure 1: The cumulative incidence plot of time from achalasia diagnosis to oesophageal cancer 
 
 
Figure 2: The cumulative incidence plot of time from achalasia diagnosis to lower respiratory tract 
infection 
 
 
Figure 3: Cumulative incidence plot of time from achalasia diagnosis to death 
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